SCHEDULE 13G/A: Polar Capital Discloses 5.65% Passive Stake in Arcutis Biotherapeutics

Polar Capital Holdings Plc and its affiliates have disclosed a 5.65% beneficial ownership stake in Arcutis Biotherapeutics, Inc. common stock, held for passive investment purposes.

Summary

• Polar Capital Holdings Plc, along with its affiliates Polar Capital LLP and Polar Capital Funds PLC Biotechnology Fund, has reported a beneficial ownership of 6,706,475 shares of Arcutis Biotherapeutics, Inc. common stock.
• This ownership represents 5.65% of the total outstanding shares of Arcutis Biotherapeutics, Inc.
• The percentage is calculated based on 118,638,235 shares outstanding, as reported in Arcutis Biotherapeutics' Form 10-K on February 25, 2025.
• The reporting persons hold sole voting power and sole dispositive power over the 6,706,475 shares.
• This filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported ownership position.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment towards the issuer's performance or outlook.

Future Outlook

NA

Industry Context

The filing indicates a significant passive investment by a specialized biotechnology fund (Polar Capital Funds PLC Biotechnology Fund) in a biotechnology company (Arcutis Biotherapeutics, Inc.), aligning with the fund's investment mandate within the healthcare and life sciences sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may influence market perception and liquidity of the company's stock.

Key Dates

Keywords

Arcutis Biotherapeutics, Polar Capital, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment, SEC Filing